Literature DB >> 32845112

Image Quality and Reliability of a Novel Dark-Blood Late Gadolinium Enhancement Sequence in Ischemic Cardiomyopathy.

Giuseppe Muscogiuri1, Marco Gatti2, Serena Dell'Aversana3, Andrea I Guaricci4, Marco Guglielmo1, Andrea Baggiano1, Daniele Andreini1,5, Saima Mushtaq1, Edoardo Conte1, Andrea Annoni1, Alberto Formenti1, Maria E Mancini1, Paola Gripari1, Martin A Janich6, Mark G Rabbat7,8, Mauro Pepi1, Gianluca Pontone1.   

Abstract

PURPOSE: The aim of this study was to assess the reliability of a 2D dark-blood phase-sensitive late gadolinium enhancement sequence (2D-DBPSLGE) compared with 2D phase-sensitive inversion recovery late gadolinium enhancement sequence (2D-BBPSLGE) in patients with ischemic cardiomyopathy (ICM).
MATERIALS AND METHODS: A total of 73 patients with a clinical history of ICM were prospectively enrolled. The following endpoints were evaluated: (a) comparison of image quality between 2D-BBPSLGE and 2D-DBPSLGE for differentiation between blood pool-late gadolinium enhancement (LGE), remote myocardium-LGE, and blood pool-remote myocardium; (b) diagnostic accuracy of 2D-DBPSLGE compared with gold standard 2D-BBPSLGE for the evaluation of infarcted segments; (c) diagnostic accuracy of 2D-DBPSLGE for the evaluation of microvascular obstruction (MVO); (d) comparison of transmurality index between 2D-BBPSLGE and 2D-DBPSLGE; (e) comparison of papillary muscle hyperenhancement between 2D-BBPSLGE and 2D-DBPSLGE; inter-reader agreement for depiction of hyperenhanced segments in both LGE sequences. Data were analyzed using paired t test, Wilcoxon test, and McNemar test, and η coefficient and intercorrelation coefficient (ICC).
RESULTS: Image quality was superior for 2D-DBPSLGE for differentiation of blood pool-LGE (P<0.001). 2D-DBPSLGE, compared with 2D-BBPSLGE, showed a sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of 96.93%, 99.89%, 99.71%, 98.78, and 99.04%, respectively. Concerning MVO detection, 2D-DBPSLGE showed a sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of 66.67%, 100.00%, 100.00%, 80.95%, and 86.21%, respectively. 2D-DBPSLGE underestimated the transmurality (P=0.007) and identified papillary muscle hyperenhancement (P<0.001). Both LGE sequences showed comparable interobserver agreement for the evaluation of infarcted areas (2D-BBPSLGE: ICC 0.99;2D-DBPSLGE: ICC 0.99).
CONCLUSIONS: Compared with 2D-BBPSLGE, 2D-DBPSLGE sequences provide better differentiation between LGE and blood-pool, while underestimating LGE trasmurality and the presence of MVO.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32845112     DOI: 10.1097/RTI.0000000000000448

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  3 in total

Review 1.  Dark-blood late gadolinium enhancement cardiovascular magnetic resonance for improved detection of subendocardial scar: a review of current techniques.

Authors:  Robert J Holtackers; Caroline M Van De Heyning; Amedeo Chiribiri; Joachim E Wildberger; René M Botnar; M Eline Kooi
Journal:  J Cardiovasc Magn Reson       Date:  2021-07-22       Impact factor: 5.364

Review 2.  Multimodality Imaging in Ischemic Chronic Cardiomyopathy.

Authors:  Giuseppe Muscogiuri; Marco Guglielmo; Alessandra Serra; Marco Gatti; Valentina Volpato; Uwe Joseph Schoepf; Luca Saba; Riccardo Cau; Riccardo Faletti; Liam J McGill; Carlo Nicola De Cecco; Gianluca Pontone; Serena Dell'Aversana; Sandro Sironi
Journal:  J Imaging       Date:  2022-02-01

Review 3.  Multimodality Imaging of Sudden Cardiac Death and Acute Complications in Acute Coronary Syndrome.

Authors:  Giuseppe Muscogiuri; Andrea Igoren Guaricci; Nicola Soldato; Riccardo Cau; Luca Saba; Paola Siena; Maria Grazia Tarsitano; Elisa Giannetta; Davide Sala; Paolo Sganzerla; Marco Gatti; Riccardo Faletti; Alberto Senatieri; Gregorio Chierchia; Gianluca Pontone; Paolo Marra; Mark G Rabbat; Sandro Sironi
Journal:  J Clin Med       Date:  2022-09-26       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.